维泊妥珠单抗联合用药在弥漫性大B细胞淋巴瘤中的应用进展  

Progress in polatuzumab vedotin combination therapies for diffuse large B-cell lymphoma

作　　者：肖羽(综述) 黄韵红(审校) Xiao Yu;Huang Yunhong(Guizhou Medical University,Guizhou,Guiyang 550004,China;不详)

机构地区：[1]贵州医科大学临床医学院,贵阳550004 [2]贵州医科大学附属肿瘤医院淋巴瘤科,贵阳550001

出　　处：《疑难病杂志》2025年第4期508-512,共5页Chinese Journal of Difficult and Complicated Cases

基　　金：贵州省卫生健康委科学技术基金项目(gzwkj2021-065)。

摘　　要：维泊妥珠单抗(Pola)是首个靶向CD79b的抗体药物偶联物,于2023年1月在我国获批联合利妥昔单抗、环磷酰胺、多柔比星和泼尼松(Pola-R-CHP)方案用于未经治疗的成人弥漫性大B细胞淋巴瘤(DLBCL)患者。基于Pola的细胞毒性作用和在信号转导通路方面的病理机制,近年来针对Pola的联合用药展开了多项研究,显示出良好的疗效和安全性,特别是在复发性或难治性DLBCL患者中,为更进一步的亚组(如老年、双/三表达)研究提供了新的方向。文章对其应用研究进展进行综述。Polatuzumab Vedotin(Pola),the inaugural antibody-drug conjugate(ADC)targeting CD79b,received approval in China in January 2023 for use in combination with rituximab,cyclophosphamide,doxorubicin,and prednisone(Pola-R-CHP)as a frontline regimen for adult patients with untreated diffuse large B-cell lymphoma(DLBCL).Leveraging the cytotoxic properties of Pola and its impact on signaling pathways implicated in the pathogenesis of DLBCL,numerous studies have explored combination therapies with Pola in recent years.These studies have demonstrated favorable efficacy and safety profiles,particularly in patients with relapsed or refractory DLBCL.The findings have paved the way for further research into the efficacy of Pola-based regimens in specific patient subgroups,such as the elderly and those with double/triple-hit DLBCL.

关 键 词：弥漫性大B细胞淋巴瘤 维泊妥珠单抗 抗体药物偶联物 CD79b 

分 类 号：R733.4[医药卫生—肿瘤]